XML 26 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies - Revenue, Investments, and R&D (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 29, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Oct. 31, 2014
Revenue Recognition              
Deferred License Revenue   $ 19,783,978   $ 19,783,978   $ 17,410,852  
Investments Available for Sale              
Fair value of investments   38,434,312   38,434,312   $ 39,482,732  
Gross unrealized gains   857   857      
Gross unrealized losses   605,080   605,080      
Realized gains   156,461          
Realized losses   183,281          
Research and Product Development              
Product development and research costs   $ 1,261,863 $ 1,246,727 $ 4,639,617 $ 2,931,577    
Baxter Healthcare Organization              
Revenue Recognition              
Deferred License Revenue             $ 20,000,000
Wanbang Biopharmaceutical              
Revenue Recognition              
Upfront payment received $ 4,000,000